Q4 Earnings Highs And Lows: Coty (NYSE:COTY) Vs The Rest Of The Personal Care Stocks Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Coty (NYSE:COTY) and its peers. While personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public’s increased desire for ethically produced goods by featuring natural ingredients in their products. The 13 personal care stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 3.7% while next quarter’s revenue guidance was 7% below. While some personal care stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 4% since the latest earnings results. Weakest Q4: Coty (NYSE:COTY) With a portfolio boasting many household brands, Coty (NYSE:COTY) is a beauty products powerhouse spanning cosmetics, fragrances, and skincare. Coty reported revenues of $1.67 billion, down 3.3% year on year. This print fell short of analysts’ expectations by 3.1%. Overall, it was a softer quarter for the company with a significant miss of analysts’ EPS estimates.Coty Total Revenue Coty delivered the weakest performance against analyst estimates of the whole group. The stock is down 18.6% since reporting and currently trades at $5.51. Read our full report on Coty here, it’s free. Best Q4: Olaplex (NASDAQ:OLPX) Rising to fame on TikTok because of its “bond building" hair products, Olaplex (NASDAQ:OLPX) offers products and treatments that repair the damage caused by traditional heat and chemical-based styling goods. Olaplex reported revenues of $100.7 million, down 9.8% year on year, outperforming analysts’ expectations by 14.4%. The business had an incredible quarter with a solid beat of analysts’ EPS estimates and an impressive beat of analysts’ EBITDA estimates.Olaplex Total Revenue Olaplex pulled off the biggest analyst estimates beat and highest full-year guidance raise among its peers. The market seems content with the results as the stock is up 1.5% since reporting. It currently trades at $1.39. Is now the time to buy Olaplex? Access our full analysis of the earnings results here, it’s free. Nature's Sunshine (NASDAQ:NATR) Started on a kitchen table in Utah, Nature’s Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. Story Continues Nature's Sunshine reported revenues of $118.2 million, up 8.5% year on year, exceeding analysts’ expectations by 8.1%. Still, it was a slower quarter as it posted a significant miss of analysts’ EBITDA and EPS estimates. As expected, the stock is down 11% since the results and currently trades at $13.01. Read our full analysis of Nature's Sunshine’s results here. Herbalife (NYSE:HLF) With the first products sold out of the trunk of the founder’s car, Herbalife (NYSE:HLF) today offers a portfolio of shakes, supplements, personal care products, and weight management programs to help customers reach their nutritional and fitness goals. Herbalife reported revenues of $1.21 billion, flat year on year. This print beat analysts’ expectations by 0.6%. It was a strong quarter as it also recorded a solid beat of analysts’ EPS estimates and an impressive beat of analysts’ EBITDA estimates. The stock is up 43.2% since reporting and currently trades at $8.05. Read our full, actionable report on Herbalife here, it’s free. Edgewell Personal Care (NYSE:EPC) Boasting brands such as Banana Boat, Schick, and Skintimate, Edgewell Personal Care (NYSE:EPC) sells personal care products in the skin and sun care, shave, and feminine care categories. Edgewell Personal Care reported revenues of $478.4 million, down 2.1% year on year. This result met analysts’ expectations. Aside from that, it was a mixed quarter as it also logged a solid beat of analysts’ EBITDA estimates. The stock is down 4% since reporting and currently trades at $30.31. Read our full, actionable report on Edgewell Personal Care here, it’s free. Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. View Comments
Q4 Earnings Highs And Lows: Coty (NYSE:COTY) Vs The Rest Of The Personal Care Stocks
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...